Asarfi Hospital Q1 FY27: Growth with improving margins, while occupancy remains a watchpoint

In Q1 FY27, consolidated revenue from operations was Rs 47.53 crore, EBITDA was Rs 9.46 crore with a 19.9% margin, and PAT was Rs 4.27 crore with a 9.0% margin.

The presentation reports Q1 FY27 total revenue of Rs 37.1 crore for the Super-Specialty Hospital Unit and Rs 9.8 crore for the Cancer Hospital Unit.

Super-specialty occupancy was 59% in Q1 FY27 (64% in Q1 FY26) with ARPOB of Rs 23,498. Cancer unit occupancy was 56% (42% in Q1 FY26) and ARPOB is reported around Rs 31k in the presentation.

The presentation cites higher patient volumes, higher surgical activity, higher OPD-to-IPD conversion, expanded consultant services, and better OT utilization as growth drivers.

The presentation states the YoY decline in Surgical Oncology revenue was due to lower complex surgery volumes and lower case realizations.

The presentation highlights a cath lab upgrade to the Philips Azurion 5 M12 system (with IVUS capability) and installation of a GE Healthcare dual-detector SPECT gamma camera at Asarfi Cancer Institute in 2026, along with the Varian TrueBeam linear accelerator.

Yes. The presentation states Asarfi Hospital Limited is planning to migrate from BSE SME to the Main Board, subject to regulatory requirements and approvals.